0001104659-23-128923.txt : 20231226 0001104659-23-128923.hdr.sgml : 20231226 20231222191548 ACCESSION NUMBER: 0001104659-23-128923 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20231222 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231226 DATE AS OF CHANGE: 20231222 FILER: COMPANY DATA: COMPANY CONFORMED NAME: STANDARD BIOTOOLS INC. CENTRAL INDEX KEY: 0001162194 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 770513190 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34180 FILM NUMBER: 231511126 BUSINESS ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502666000 MAIL ADDRESS: STREET 1: 2 TOWER PLACE STREET 2: SUITE 2000 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: FLUIDIGM CORP DATE OF NAME CHANGE: 20011113 8-K 1 tm2333662d1_8k.htm FORM 8-K
false 0001162194 0001162194 2023-12-22 2023-12-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 22, 2023

 

 

Standard BioTools Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware   001-34180   77-0513190
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification No.)

         
2 Tower Place, Suite 2000    
South San Francisco, California   94080
(Address of Principal Executive Offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (650) 266-6000

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

x Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share LAB Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01. Other Events.

 

On December 22, 2023, Standard BioTools Inc. (“Standard BioTools” or the “Company”) issued a press release titled “ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic”, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference.

 

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Press Release of Standard BioTools Inc., dated as of December 22, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

Additional Information and Where to Find It

 

As previously disclosed, on October 4, 2023, Standard BioTools, SomaLogic, Inc., a Delaware corporation (“SomaLogic”), and Martis Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Merger Sub”), entered into an Agreement and Plan of Merger, pursuant to which, among other matters, Merger Sub will merge with and into SomaLogic (the “Merger”), with SomaLogic surviving the Merger as a wholly owned subsidiary of the Company. In connection with the Merger and required stockholder approval, Standard BioTools filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended (the “Form S-4”), which was declared effective by the SEC on December 1, 2023. The Form S-4 includes a definitive joint proxy statement of Standard BioTools and SomaLogic and also constitutes a final prospectus of Standard BioTools. The definitive joint proxy statement was mailed or otherwise made available to stockholders of Standard BioTools and SomaLogic on or about December 4, 2023. Standard BioTools’ and SomaLogic’s stockholders are urged to carefully read the joint proxy statement/prospectus (including all amendments, supplements and any documents incorporated by reference therein) and other relevant materials filed or to be filed with the SEC and in their entirety because they contain important information about the Merger and the parties to the Merger. Investors and stockholders may obtain free copies of these documents and other documents filed with the SEC at its website at http://www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC by Standard BioTools at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

 

Participants in the Solicitation

 

Standard BioTools, SomaLogic and each of their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from Standard BioTools’ stockholders with respect to the Merger. Information about Standard BioTools’ directors and executive officers, including their ownership of Standard BioTools’ securities, is set forth in the joint proxy statement/prospectus, Standard BioTools’ proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023, Current Reports on Form 8-K, which were filed with the SEC on May 3, 2023, May 15, 2023, June 16, 2023 and July 28, 2023, and Standard BioTools’ other filings with the SEC. Information concerning SomaLogic’s directors and executive officers, including their ownership of SomaLogic securities, is set forth in the joint proxy statement/prospectus, SomaLogic’s proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 25, 2023, Current Reports on Form 8-K, which were filed with the SEC on June 6, 2023, as amended on June 14, 2023, June 9, 2023, October 4, 2023 and December 12, 2023, and SomaLogic’s other filings with the SEC. Investors may obtain more detailed information regarding the direct and indirect interests of Standard BioTools and its respective executive officers and directors in the Merger, which may be different than those of Standard BioTools’ stockholders generally, by reading the definitive proxy statements regarding the Merger, which have been filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov, at http://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

 

 

 

 

No Offer or Solicitation

 

This Current Report on Form 8-K and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

 

Forward-Looking Statements

 

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of the management of Standard BioTools and SomaLogic that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements, many of which are beyond the control of Standard BioTools and SomaLogic. All statements other than statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the Merger; the ability of the parties to complete the Merger considering the various closing conditions; and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties’ current expectations and are necessarily subject to associated risks related to, among other things, (i) the risk that the Merger may not be completed in a timely manner or at all, which may adversely affect Standard BioTools’ and SomaLogic’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the Merger and the potential failure to satisfy the conditions to the consummation of the Merger, including obtaining stockholder and regulatory approvals; (iii) the Merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the Merger on the ability of Standard BioTools or SomaLogic to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Standard BioTools or SomaLogic does business, or on Standard BioTools’ or SomaLogic’s operating results and business generally; (v) Standard BioTools’ or SomaLogic’s respective businesses may suffer as a result of uncertainty surrounding the Merger and disruption of management’s attention due to the Merger; (vi) the outcome of any legal proceedings related to the Merger or otherwise, or the impact of the Merger thereupon; (vii) Standard BioTools or SomaLogic may be adversely affected by other economic, business and/or competitive factors, (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger agreement and the Merger; (ix) restrictions during the pendency of the Merger that may impact Standard BioTools’ or SomaLogic’s ability to pursue certain business opportunities or strategic transactions; (x) the risk that Standard BioTools or SomaLogic may be unable to obtain governmental and regulatory approvals required for the Merger, or that required governmental and regulatory approvals may delay the consummation of the Merger or result in the imposition of conditions that could reduce the anticipated benefits from the Merger or cause the parties to abandon the Merger; (xi) risks that the anticipated benefits of the Merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of the Standard BioTools shares to be issued in the Merger; (xiv) the risk that post-closing integration of the Merger may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the Merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company’s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of Standard BioTools’ and SomaLogic’s traded securities; (xvi) the lingering effects of the COVID-19 pandemic on Standard BioTools’ and SomaLogic’s industry and individual companies, including on counterparties, the supply chain, the execution of research and development programs, access to financing and the allocation of government resources; (xvii) the ability of Standard BioTools or SomaLogic to protect and enforce intellectual property rights; and (xviii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as Standard BioTools’ and SomaLogic’s response to any of the aforementioned factors. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent quarterly report on Form 10-Q filed with the SEC on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 14, 2023 and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 28, 2023 and in SomaLogic’s other filings with the SEC. The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Standard BioTools and SomaLogic and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this Current Report on Form 8-K. While Standard BioTools and SomaLogic may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: December 22, 2023 STANDARD BIOTOOLS INC.
     
  By: /s/ Jeffrey Black
  Name: Jeffrey Black
  Title: Chief Financial Officer

 

 

 

 EX-99.1 2 tm2333662d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

ISS Recommends Standard BioTools Stockholders Vote “FOR” All Proposals Relating to Proposed Merger with SomaLogic

 

SOUTH SAN FRANCISCO, Calif. -- December 22, 2023 – Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health - today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that Standard BioTools stockholders vote “FOR” all proposals relating to the pending merger with SomaLogic at the Company’s upcoming Special Meeting of Stockholders to be held on January 4, 2024. The Company issued the following statement:

 

Our merger with SomaLogic presents a compelling value proposition for all stockholders through a significantly accelerated path to profitability and bolstered capital structure to fuel future growth. We are pleased with ISS’ recommendation and look forward to completing the merger in the first quarter of 2024.

 

A special meeting of Standard BioTools stockholders is scheduled to be held virtually in connection with the proposed merger on January 4, 2024, at 12:00 p.m. ET (10:00 a.m. MT / 9:00 a.m. PT). Standard BioTools stockholders who need assistance voting or have questions regarding the Special Meeting may contact Standard BioTools’ proxy solicitor, Alliance Advisors LLC, at (800) 574-5969.

 

The merger remains on track to close in the first quarter of 2024, subject to approval by SomaLogic and Standard BioTools stockholders and satisfaction of other customary closing conditions.

 

About Standard BioTools Inc.

 

Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbio.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, “Unleashing tools to accelerate breakthroughs in human health,” Hyperion, Hyperion XTi, XTi, and X9 are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

 

 

 

 

Additional Information and Where to Find It

 

In connection with the merger and required stockholder approval, Standard BioTools filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended (the “Form S-4”), which was declared effective by the SEC on December 1, 2023. The Form S-4 includes a definitive joint proxy statement of Standard BioTools and SomaLogic and also constitutes a final prospectus of Standard BioTools. The definitive joint proxy statement was mailed or otherwise made available to stockholders of Standard BioTools and SomaLogic on or about December 4, 2023. Standard BioTools’ and SomaLogic’s stockholders are urged to carefully read the joint proxy statement/prospectus (including all amendments, supplements and any documents incorporated by reference therein) and other relevant materials filed or to be filed with the SEC and in their entirety because they contain important information about the merger and the parties to the merger. Investors and stockholders may obtain free copies of these documents and other documents filed with the SEC at its website at http://www.sec.gov. In addition, investors may obtain free copies of the documents filed with the SEC by Standard BioTools at http://investors.standardbio.com or contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

 

Participants in the Solicitation

 

Standard BioTools, SomaLogic and each of their respective executive officers and directors may be deemed to be participants in the solicitation of proxies from Standard BioTools stockholders with respect to the merger. Information about Standard BioTools’ directors and executive officers, including their ownership of Standard BioTools’ securities, is set forth in the joint proxy statement/prospectus, Standard BioTools’ proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023, Current Reports on Form 8-K, which were filed with the SEC on May 3, 2023, May 15, 2023, June 16, 2023 and July 28, 2023, and Standard BioTools’ other filings with the SEC. Information concerning SomaLogic’s directors and executive officers, including their ownership of SomaLogic securities, is set forth in the joint proxy statement/prospectus, SomaLogic’s proxy statement for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 25, 2023, Current Reports on Form 8-K, which were filed with the SEC on June 6, 2023, as amended on June 14, 2023, June 9, 2023, October 4, 2023 and December 12, 2023, and SomaLogic’s other filings with the SEC. Investors may obtain more detailed information regarding the direct and indirect interests of Standard BioTools and its respective executive officers and directors in the merger, which may be different than those of Standard BioTools’ stockholders generally, by reading the definitive proxy statements regarding the merger, which have been filed with the SEC. These documents are available free of charge at the SEC’s website at www.sec.gov, at http://investors.standardbio.com or by contacting Standard BioTools’ Investor Relations department at investors@standardbio.com or at https://investors.somalogic.com or by contacting SomaLogic Investor Relations at investors@somalogic.com.

 

No Offer or Solicitation

 

This press release and the information contained herein shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

 

 

 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon current plans, estimates and expectations of the management of Standard BioTools and SomaLogic that are subject to various risks and uncertainties that could cause actual results to differ materially from such statements, many of which are beyond the control of Standard BioTools and SomaLogic. All statements other than statements of historical fact (including statements containing the words “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are statements that could be deemed forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. Forward-looking statements may include statements regarding the expected timing of the closing of the merger; the ability of the parties to complete the merger considering the various closing conditions; and any assumptions underlying any of the foregoing. Statements regarding future events are based on the parties’ current expectations and are necessarily subject to associated risks related to, among other things, (i) the risk that the Merger may not be completed in a timely manner or at all, which may adversely affect Standard BioTools’ and SomaLogic’s businesses and the price of their respective securities; (ii) uncertainties as to the timing of the consummation of the merger and the potential failure to satisfy the conditions to the consummation of the merger, including obtaining stockholder and regulatory approvals; (iii) the merger may involve unexpected costs, liabilities or delays; (iv) the effect of the announcement, pendency or completion of the merger on the ability of Standard BioTools or SomaLogic to retain and hire key personnel and maintain relationships with customers, suppliers and others with whom Standard BioTools or SomaLogic does business, or on Standard BioTools’ or SomaLogic’s operating results and business generally; (v) Standard BioTools’ or SomaLogic’s respective businesses may suffer as a result of uncertainty surrounding the merger and disruption of management’s attention due to the merger; (vi) the outcome of any legal proceedings related to the merger or otherwise, or the impact of the merger thereupon; (vii) Standard BioTools or SomaLogic may be adversely affected by other economic, business and/or competitive factors, (viii) the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement and the merger; (ix) restrictions during the pendency of the merger that may impact Standard BioTools’ or SomaLogic’s ability to pursue certain business opportunities or strategic transactions; (x) the risk that Standard BioTools or SomaLogic may be unable to obtain governmental and regulatory approvals required for the merger, or that required governmental and regulatory approvals may delay the consummation of the merger or result in the imposition of conditions that could reduce the anticipated benefits from the merger or cause the parties to abandon the merger; (xi) risks that the anticipated benefits of the merger or other commercial opportunities may otherwise not be fully realized or may take longer to realize than expected; (xii) the impact of legislative, regulatory, economic, competitive and technological changes; (xiii) risks relating to the value of the Standard BioTools shares to be issued in the merger; (xiv) the risk that post-closing integration of the merger may not occur as anticipated or the combined company may not be able to achieve the benefits expected from the merger, as well as the risk of potential delays, challenges and expenses associated with integrating the combined company’s existing businesses; (xv) exposure to inflation, currency rate and interest rate fluctuations, as well as fluctuations in the market price of Standard BioTools’ and SomaLogic’s traded securities; (xvi) the lingering effects of the COVID-19 pandemic on Standard BioTools’ and SomaLogic’s industry and individual companies, including on counterparties, the supply chain, the execution of research and development programs, access to financing and the allocation of government resources; (xvii) the ability of Standard BioTools or SomaLogic to protect and enforce intellectual property rights; and (xviii) the unpredictability and severity of catastrophic events, including, but not limited to, acts of terrorism or outbreak of war or hostilities, as well as Standard BioTools’ and SomaLogic’s response to any of the aforementioned factors. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. For information regarding other related risks, see the “Risk Factors” section of Standard BioTools’ most recent quarterly report on Form 10-Q filed with the SEC on November 7, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 14, 2023 and in Standard BioTools’ other filings with the SEC, as well as the “Risk Factors” section of SomaLogic’s most recent quarterly report on Form 10-Q filed with the SEC on November 8, 2023, on its most recent annual report on Form 10-K filed with the SEC on March 28, 2023 and in SomaLogic’s other filings with the SEC. The risks and uncertainties described above and in the SEC filings cited above are not exclusive and further information concerning Standard BioTools and SomaLogic and their respective businesses, including factors that potentially could materially affect their respective businesses, financial conditions or operating results, may emerge from time to time. Readers are urged to consider these factors carefully in evaluating these forward-looking statements, and not to place undue reliance on any forward-looking statements. Any such forward-looking statements represent management’s reasonable estimates and beliefs as of the date of this press release. While Standard BioTools and SomaLogic may elect to update such forward-looking statements at some point in the future, they disclaim any obligation to do so, other than as may be required by law, even if subsequent events cause their views to change.

 

 

 

 

Contacts

 

Investors

 

Standard BioTools

Peter DeNardo

CapComm Partners

ir@standardbio.com

 

Media

 

Nick Lamplough / Dan Moore / Tali Epstein

Collected Strategies

LAB-CS@collectedstrategies.com

 

 

 

 EX-101.SCH 3 lab-20231222.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 lab-20231222_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 lab-20231222_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Cover
Dec. 22, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 22, 2023
Entity File Number 001-34180
Entity Registrant Name Standard BioTools Inc.
Entity Central Index Key 0001162194
Entity Tax Identification Number 77-0513190
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2 Tower Place
Entity Address, Address Line Two Suite 2000
Entity Address, City or Town South San Francisco
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 266-6000
Written Communications true
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.001 per share
Trading Symbol LAB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 7 tm2333662d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001162194 2023-12-22 2023-12-22 iso4217:USD shares iso4217:USD shares false 0001162194 8-K 2023-12-22 Standard BioTools Inc. DE 001-34180 77-0513190 2 Tower Place Suite 2000 South San Francisco CA 94080 650 266-6000 true false false false Common stock, par value $0.001 per share LAB NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://standardbio/role/Cover Cover Cover 1 false false All Reports Book All Reports lab-20231222.xsd lab-20231222_lab.xml lab-20231222_pre.xml tm2333662d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333662d1_8k.htm": { "nsprefix": "LAB", "nsuri": "http://standardbio/20231222", "dts": { "schema": { "local": [ "lab-20231222.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "lab-20231222_lab.xml" ] }, "presentationLink": { "local": [ "lab-20231222_pre.xml" ] }, "inline": { "local": [ "tm2333662d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://standardbio/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333662d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-22", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333662d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://standardbio/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 14 0001104659-23-128923-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-128923-xbrl.zip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